Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

(2012) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Accelerated infusion rates of rituximab are well tolerated and safe in rheumatology practice: a single-centre experience

(2012) Meryem Can et al.   CLINICAL RHEUMATOLOGY

Rapid infusion with rituximab: short term safety in systemic autoimmune diseases

(2011) Janni Lisander Larsen et al.   RHEUMATOLOGY INTERNATIONAL

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))

(2010) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and Safety of Retreatment in Patients with Rheumatoid Arthritis with Previous Inadequate Response to Tumor Necrosis Factor Inhibitors: Results from the SUNRISE Trial

(2010) P. J. MEASE et al.   JOURNAL OF RHEUMATOLOGY

Review of the Safety and Feasibility of Rapid Infusion of Rituximab

(2010) Jill Atmar   Journal of Oncology Practice

Rapid infusion of rituximab over 60 min

(2009) Mark Tuthill et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies

(2008) E Keystone et al.   ANNALS OF THE RHEUMATIC DISEASES

Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Therapy

(2008) C. H. Chung   ONCOLOGIST